Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 8/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.34 |
| ▸ | EZH2 | Q15910 | 9/20 | 0.34 |
| ▸ | EED | O75530 | 8/20 | 0.34 |
| ▸ | RBBP4 | Q09028 | 8/20 | 0.34 |
| ▸ | SUZ12 | Q15022 | 8/20 | 0.34 |
| ▸ | AEBP2 | Q6ZN18 | 8/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19964858 | 0.89 | ATR (0.40) | ATRCYP4F2CYP4A11EZH2HCRTR1 | |
| SCHEMBL28886622 | 0.89 | CYP4F2 (0.35) | ATRCYP4F2CYP4A11EZH2HCRTR1 | |
| SCHEMBL21113205 | 0.87 | EED (0.45) | ATRCYP4F2CYP4A11EZH2EED | |
| SCHEMBL21113320 | 0.79 | EZH2 (0.38) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21113520 | 0.78 | EZH2 (0.49) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL21113275 | 0.78 | LRRK2 (0.33) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19964855 | 0.77 | EED (0.47) | ATRCYP4F2CYP4A11EZH2EED | |
| SCHEMBL28886644 | 0.77 | EED (0.40) | ATRCYP4F2CYP4A11EZH2EED | |
| SCHEMBL19964809 | 0.75 | CYP4F2 (0.42) | ATRCYP4F2CYP4A11HCRTR1HCRTR2 | |
| SCHEMBL21157318 | 0.75 | EZH2 (0.44) | ATREZH2EEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| EP-3524602-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524602-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | HAIHE BIOPHARMA CO. LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968215-B2 | Pyrido five-element aromatic ring compound, preparation method therefor and use thereof | EZH2, IKZF2, SUZ12 | ATR 1112/4885CYP4F2 768/4885CYP4A11 251/4885 |
| US-20190211010-A1 | PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | EZH2, IKZF2, SUZ12 | ATR 1112/4885CYP4F2 768/4885CYP4A11 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.